Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor antagonist is safe and effective for treatment of prurigo nodularis versus placebo.


Clinical Trial Description

The sensation of itch is transmitted to the brain through the nervous system. Several chemicals are involved in transmitting this signal.This trial of VPD 737 is intended to treat this condition by blocking one of the chemicals involved in the transmission of the itch signal. This is an oral drug administered once daily It has been used in other trials and has shown to be safe at the doses used in this trial. The trial will involve once daily pills for 8 weeks. Subject will be asked to fill out questionnaires both electronically and on paper during the study period. Patients will also be monitored for safety and will have blood taken for testing and several points during the trial. Overall participation will last about 14 weeks ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02196324
Study type Interventional
Source Vyne Therapeutics Inc.
Contact
Status Completed
Phase Phase 2
Start date July 9, 2014
Completion date June 10, 2016

See also
  Status Clinical Trial Phase
Completed NCT05038982 - Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin Phase 2
Completed NCT00869089 - Safety and Efficacy of CC-10004 for Prurigo Nodularis Phase 2
Completed NCT04501666 - An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis Phase 3
Completed NCT03181503 - Safety and Efficacy of Nemolizumab in PN Phase 2
Completed NCT03630198 - Pain Outcomes Following Intralesional Corticosteroid Injections Phase 4
Completed NCT04944862 - A Study of CDX-0159 in Patients With Prurigo Nodularis Phase 1
Active, not recruiting NCT05061693 - A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis Phase 2
Completed NCT03546816 - Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis Phase 3
Not yet recruiting NCT06201715 - Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis N/A
Completed NCT02174419 - Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis Phase 2/Phase 3
Terminated NCT03540160 - Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) Phase 3
Completed NCT03816891 - Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis Phase 2
Recruiting NCT05764161 - A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) Phase 3
Recruiting NCT03576287 - Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis Phase 1/Phase 2
Completed NCT05052983 - A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis Phase 3
Active, not recruiting NCT04204616 - A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Phase 3
Not yet recruiting NCT06293053 - A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis Phase 3
Recruiting NCT06213831 - A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream Phase 1
Not yet recruiting NCT04681300 - Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non-atopic Prurigo Nodularis (of Hyde) Using Single Cell RNA-sequencing
Recruiting NCT06087627 - A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine